Selwood Asset Management advocates for Louis Hachette market listing change - Global Banking & Finance Review
The image illustrates Selwood Asset Management's proposal for Louis Hachette to change its stock market listing, emphasizing potential growth and visibility in the finance sector.
Finance

US FDA approves Sanofi's bleeding disorder therapy

Published by Global Banking & Finance Review

Posted on March 28, 2025

1 min read

· Last updated: March 28, 2025

Add as preferred source on Google

FDA Approves Sanofi's New Therapy for Bleeding Disorders

(Reuters) -The U.S. Food and Drug Administration approved French drugmaker Sanofi's therapy, paving the way for a new type of treatment for patients 12 years of age and older with a rare disorder that prevents blood from clotting properly, the regulator said on Friday.

(Reporting by Padmanabhan Ananthan and Sriparna Roy in Bengaluru; Editing by Shailesh Kuber)

Key Takeaways

  • FDA approves Sanofi's new bleeding disorder therapy.
  • The therapy targets patients aged 12 and older.
  • It addresses a rare disorder affecting blood clotting.
  • Sanofi's treatment offers a novel approach.
  • Approval marks a significant milestone for Sanofi.

Frequently Asked Questions

What is the main topic?
The main topic is the FDA's approval of Sanofi's new therapy for a rare bleeding disorder.
Who is the therapy intended for?
The therapy is intended for patients aged 12 and older with a rare bleeding disorder.
Why is this approval significant?
This approval is significant as it introduces a novel treatment option for a rare condition.

Related Articles

More from Finance

Explore more articles in the Finance category